Elutia's Q2 revenue falls on SimpliDerm production disruption - ELUT News | RalliesElutia's Q2 revenue falls on SimpliDerm production disruption
E
ELUT• Result drivers
- SimpliDerm disruption - Revenue fell due to a $0.7 million reduction in SimpliDerm sales from a contract manufacturing production disruption.
- Litigation costs - Operating expenses decreased, driven by a $1.9 million reduction in net litigation costs.
- R&D spending - Research and development expenses rose $1.5 million to support the NXT-41 and NXT-41x programs.
Quarterly results
- Elutia's Q2 revenue declined year over year due to SimpliDerm production disruption.
- Q2 revenue was $2.43 million, compared with a consensus estimate of $2.90 million from one analyst.
- Q2 loss per share was $0.17.
- Q2 net loss narrowed to $7.65 million from $9.6 million a year earlier.
- Q2 gross profit was $1.45 million.
- Q2 income from operations was .
-$7.96 million
Q2 operating expenses were $9.4 million.Capital and analyst coverage
- The company said it secured up to $26 million in new capital without an equity offering.
- The one available analyst rating on the shares is "buy".
- The average consensus recommendation for the pharmaceuticals peer group is "buy".
- Wall Street's median 12-month price target for Elutia Inc is $5.00, about 511.2% above its August 12 closing price of $0.82.
Outlook for NXT-41 and NXT-41x
- Elutia expects an FDA clearance decision for NXT-41 in 4Q 2026.
- The company anticipates an FDA clearance decision for NXT-41x in 1H 2027.
- Elutia plans a full commercial launch of NXT-41x in 2028.
